Similarly, it has been reported that EZH2 inhibitors can reprogram the tumor microenvironment and enhance T-cell-mediated anti-tumor immunity, suggesting a translational synergy with immunotherapy [210]. The gene discussed is EZH2; the disease is neoplasm.